Table 2.
Clinical characteristics based on the macroscopic lesion scorea.
| Overall n = 190 | 0b | 1 | 2 | 3 or more | p-Valuec | |
|---|---|---|---|---|---|---|
| Demographicsd | ||||||
| Age, mean (S.D.), years | 84.4 (9.6) | 82.3 (10.4) | 87.8 (4.7) | 84.3 (8.3) | 88.5 (9.2) | 0.003 |
| Female (%) | 65.3 | 58.8 | 69.2 | 76.7 | 71.9 | 0.2 |
| Clinicopathologic interval, monthe | 13 (6–27) | 11.5 (5–26) | 11 (6–16) | 17.5 (9–31) | 14 (6.5–29) | 0.7 |
| APOE e4 allele (%) | 14.7 | 16.7 | 3.9 | 13.3 | 18.8 | 0.4f |
| Clinical diagnosis at last evaluation (%) | ||||||
| Non-demented (n = 59) | 31.1 | 40.2 | 30.8 | 23.3 | 9.4 | 0.001 |
| AD (n = 84) | 44.2 | 47.1 | 38.5 | 40.0 | 43.8 | |
| VaD (n = 28) | 14.7 | 3.9 | 19.2 | 30.0 | 31.3 | |
| Other (n = 19) | 10.0 | 8.8 | 11.5 | 6.7 | 15.6 | 0.1 |
| Blessed score (n = 184)e | 15 (4–32) | 9 (3–32) | 14.5 (4–26) | 16 (6–32) | 21 (12–32) | 0.1 |
| Pathological lesions (%) | ||||||
| Large infarcts | ||||||
| 1 | 9.0 | – | 26.9 | 3.3 | 28.1 | – |
| ≥2 | 10.0 | – | – | 26.7 | 34.4 | – |
| Lacunes | ||||||
| 1 | 11.1 | – | 53.9 | 6.7 | 15.6 | – |
| ≥2 | 14.2 | – | – | 23.3 | 62.5 | – |
| Leukoencephalopathy | ||||||
| Mild | 6.8 | – | 19.2 | 3.3 | 21.9 | – |
| Mod-severe | 16.8 | – | – | 43.3 | 59.4 | – |
| Microinfarcts | 15.8 | 9.8 | 11.5 | 30.0 | 25.0 | 0.02c |
| Cribriform changes | 15.8 | 3.9 | 26.9 | 16.7 | 43.8 | <0.001c |
| CAA | 27.9 | 27.5 | 23.1 | 46.7 | 15.6 | 0.05c |
| Braak NFT stage, mean (S.D.) | 3.4 (1.8) | 3.3 (2.0) | 3.0 (1.7) | 3.8 (1.8) | 3.5 (1.7) | 0.5 |
| Cortical Lewy bodies (%) | 12.6 | 9.8 | 11.5 | 20.0 | 15.6 | 0.5 |
a
Macroscopic vascular lesions score ranging 0–6 as outlined in Table 4.
b
Defined as absence of any macroscopic vascular lesions such as large infarcts, lacunar infarct, or leukoencephalopathy.
c
Using ANOVA for continuous variables, and Chi-square test for categorical variables.
d
Mean (±S.D.) unless otherwise specified.
e
Median, 25–75% quantiles.
f
APOE missing in 87 cases.